Prelude Therapeutics Incorporated
HealthcareNASDAQ:PRLD · NASDAQ Global Select
+$0.38 today
Vol 0.31M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-145.0%
avg -37.2%
ROIC
-114.8%
avg -82.1%
ROA
-70.4%
avg -64.6%
Analysis
ROA is currently the strongest return metric at -70.4% versus its period average of -64.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Krishna Vaddi | Founder, Chief Executive Officer & Director | $935,256.00 | — | 60 | $837,000.00 | 1.07% |
Bryant David Lim | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | $681,050.00 | — | 55 | $38,000.00 | 0.05% |
Peggy A. Scherle | Chief Scientific Officer | $674,206.00 | — | 64 | $230,000.00 | 0.29% |
Andrew Combs | Executive Vice President & Chief Chemistry Officer | $562,461.00 | — | 59 | $230,000.00 | 0.29% |
Charles Q. Morris MRCP | Chief Medical Officer | — | — | 61 | $450,000.00 | 0.57% |
Madhu Pudipeddi | Senior Vice President of Technical Operations | — | — | — | — | — |
Wan-Jen Hong | Senior Vice President of Clinical Development | — | — | 47 | — | — |
Naveen Babbar | Senior Vice President of Translation Medicine | — | — | — | — | — |
Robert A. Doody Jr. | Senior Vice President of Investor Relations | — | — | — | — | — |
Sean Brusky | Chief Business Officer | — | — | 48 | $0.00 | <0.01% |
Sri Sahasranaman | Senior Vice President of Clinical Pharmacology | — | — | — | — | — |
Aimee Crombie | Senior Vice President and Head of Strategic Planning & Operations | — | — | — | — | — |
Michele Porreca | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$25.00M
Sells
0
$0.00
Net Sentiment
+$25.00M
Net buying
Most Active
Bonita David P
2 transactions
Analysis
Insiders reported 6 buys worth $25.00M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $25.00M. Bonita David P was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages PRLD?
Prelude Therapeutics Incorporated (PRLD) lists 13 active executives. The top listed executive is Andrew Combs, Executive Vice President & Chief Chemistry Officer.
Are PRLD insiders buying or selling?
Recent insider activity shows net buying of $66.86M.
Explore More
Continue the stock analysis
Jump to another research area for this company.